Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail

Journal of Controlled Release

Volumn 167, Issue 3, 2013, Pages 301-314

  Vitorino, C ^a   Almeida, J ^b   Goncalves L M ^c   Almeida, A J ^c   Sousa, J J ^a   Pais, A A C C ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Co encapsulation; Molecular dynamics; Nanostructured lipid carriers; Permeation enhancement; Transdermal administration; Two step factorial design

Indexed keywords

CO-ENCAPSULATION; FACTORIAL DESIGN; NANOSTRUCTURED LIPID CARRIERS; PERMEATION ENHANCEMENT; TRANSDERMAL ADMINISTRATION;

LIPID BILAYERS; MOLECULAR DYNAMICS;

DRUG PRODUCTS;

DRUG CARRIER; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; OLANZAPINE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG FORMULATION; DRUG PENETRATION; EXPERIMENTAL DESIGN; FACTORIAL DESIGN; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; LIPID BILAYER; MICROENCAPSULATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DRUG CARRIERS; DRUG DESIGN; FIBROBLASTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR DYNAMICS SIMULATION; NANOSTRUCTURES; PERMEABILITY; SIMVASTATIN; SKIN; SKIN ABSORPTION; SWINE; TRIGLYCERIDES;

EID: 84874943703     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.02.011     Document Type: Article

References (78)

1. W. Kenneth, and R. Michael The structure and function of skin Dermatological and Transdermal Formulations 2002 Informa Healthcare
2. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170
3. V. Jenning, M. Schäfer-Korting, and S. Gohla Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties J. Control. Release 66 2000 115 126
4. R.H. Müller, R.D. Petersen, A. Hommoss, and J. Pardeike Nanostructured lipid carriers (NLC) in cosmetic dermal products Adv. Drug Deliv. Rev. 59 2007 522 530
5. V. Sanna, G. Caria, and A. Mariani Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate Powder Technol. 201 2010 32 36
6. C. Puglia, and F. Bonina Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals Expert Opin. Drug Deliv. 9 2012 429 441
7. J.T. Kantrowitz, and L. Citrome Olanzapine: review of safety 2008 Expert Opin. Drug Saf. 7 2008 761 769
8. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, R.S.E. Keefe, S.M. Davis, C.E. Davis, B.D. Lebowitz, J. Severe, and J.K. Hsiao Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 353 2005 1209 1223
9. J.P. McEvoy, J.M. Meyer, D.C. Goff, H.A. Nasrallah, S.M. Davis, L. Sullivan, H.Y. Meltzer, J. Hsiao, T. Scott Stroup, and J.A. Lieberman Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophr. Res. 80 2005 19 32
10. R.M. Capasso, T.W. Lineberry, J.M. Bostwick, P.A. Decker, and J. St. Sauver Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005 Schizophr. Res. 98 2008 287 294
11. S. Saha, D. Chant, and J. McGrath A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64 2007 1123 1131
12. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, J. Kjekshus, and f.t.S.S.S.S. Group Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
13. G. Heart Protection Study Collaborative Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial Lancet 378 2011 2013 2020
14. M.C. Mauri, L.S. Volonteri, A. Colasanti, A. Fiorentini, I.F. De Gaspari, and S.R. Bareggi Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clin. Pharmacokinet. 46 2007 359 388
15. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam. Clin. Pharmacol. 19 2005 117 125
16. A. Alexander, S. Dwivedi, T.K. Giri Ajazuddin, S. Saraf, S. Saraf, and D.K. Tripathi Approaches for breaking the barriers of drug permeation through transdermal drug delivery J. Control. Release 164 2012 26 40
17. C. Vitorino, F.A. Carvalho, A.J. Almeida, J.J. Sousa, and A.A.C.C. Pais The size of solid lipid nanoparticles: an interpretation from experimental design Colloids Surf. B: Biointerfaces 84 2011 117 130
18. M. Joshi, and V. Patravale Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib Drug Dev. Ind. Pharm. 32 2006 911 918
19. J. Pardeike, A. Hommoss, and R.H. Müller Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products Int. J. Pharm. 366 2009 170 184
20. ISO13321 Methods for determination of particle size distribution part 8: photon correlation spectroscopy 1996 International Organisation for Standardisaton (ISO)
21. ISO22412 Particle Size Analysis - Dynamic Light Scattering 2008 International Organisation for Standardisation (ISO)
22. S. Doktorovova, and E.B. Souto Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review Expert Opin. Drug Deliv. 6 2009 165 176
23. J.W. Eaton GNU Octave Software, Version 3.2.3 2009
24. W. Kenneth, W. Adam, and B. Keith Methods for studying percutaneous absorption Dermatological and Transdermal Formulations 2002 Informa Healthcare
25. V.B. Junyaprasert, V. Teeranachaideekul, E.B. Souto, P. Boonme, and R.H. Müller Q10-loaded NLC versus nanoemulsions: stability, rheology and in vitro skin permeation Int. J. Pharm. 377 2009 207 214
26. V. Kassis, and J. Søndergaard Heat-separation of normal human skin for epidermal and dermal prostaglandin analysis Arch. Dermatol. Res. 273 1982 301 306
27. B. Finnin, K.A. Walters, and T.J. Franz In vitro skin permeation methodology Transdermal and Topical Drug Delivery 2011 John Wiley & Sons, Inc. 85 108
28. Q. Lv, A. Yu, Y. Xi, H. Li, Z. Song, J. Cui, F. Cao, and G. Zhai Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery Int. J. Pharm. 372 2009 191 198
29. S.D. Mandawgade, and V.B. Patravale Development of SLNs from natural lipids: application to topical delivery of tretinoin Int. J. Pharm. 363 2008 132 138
30. S.K. Li, W. Suh, H.H. Parikh, A.-H. Ghanem, S.C. Mehta, K.D. Peck, and W.I. Higuchi Lag time data for characterizing the pore pathway of intact and chemically pretreated human epidermal membrane Int. J. Pharm. 170 1998 93 108
31. L. Kang, C.W. Yap, P.F.C. Lim, Y.Z. Chen, P.C. Ho, Y.W. Chan, G.P. Wong, and S.Y. Chan Formulation development of transdermal dosage forms: quantitative structure-activity relationship model for predicting activities of terpenes that enhance drug penetration through human skin J. Control. Release 120 2007 211 219
32. A.F. El-Kattan, C.S. Asbill, and B.B. Michniak The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems Int. J. Pharm. 198 2000 179 189
33. M. Aqil, A. Ahad, Y. Sultana, and A. Ali Status of terpenes as skin penetration enhancers Drug Discov. Today 12 2007 1061 1067
34. B. Sapra, S. Jain, and A. Tiwary Percutaneous permeation enhancement by terpenes: mechanistic view AAPS J. 10 2008 120 132
35. W.F.D. Bennett, J.L. MacCallum, and D.P. Tieleman Thermodynamic analysis of the effect of cholesterol on dipalmitoylphosphatidylcholine lipid membranes J. Am. Chem. Soc. 131 2009 1972 1978
36. J.A.S. Almeida, E.F. Marques, A.S. Jurado, and A.A.C.C. Pais The effect of cationic gemini surfactants upon lipid membranes. An experimental and molecular dynamics simulation study Phys. Chem. Chem. Phys. 12 2010 14462 14476
37. A. Kukol Lipid models for united-atom molecular dynamics simulations of proteins J. Chem. Theory Comput. 5 2009 615 626
38. I. Kyrikou, S.K. Hadjikakou, D. Kovala-Demertzi, K. Viras, and T. Mavromoustakos Effects of non-steroid anti-inflammatory drugs in membrane bilayers Chem. Phys. Lipids 132 2004 157 169
39. A.A. Gurtovenko, and J. Anwar Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide J. Phys. Chem. B 111 2007 10453 10460
40. R. Notman, M. Noro, B. O'Malley, and J. Anwar Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes J. Am. Chem. Soc. 128 2006 13982 13983
41. J. Cerezo, J. Zúñiga, A. Bastida, A. Requena, and J.P. Cerón-Carrasco Atomistic molecular dynamics simulations of the interactions of oleic and 2-hydroxyoleic acids with phosphatidylcholine bilayers J. Phys. Chem. B 115 2011 11727 11738
42. J.A.S. Almeida, H. Faneca, R.A. Carvalho, E.F. Marques, and A.A.C.C. Pais Dicationic alkylammonium bromide gemini surfactants. Membrane perturbation and skin irritation PLoS One 6 2011 e26965
43. L.D. Schuler, X. Daura, and W.F. Van Gunsteren An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase J. Comput. Chem. 22 2001 1205 1218
44. T.J. Piggot, Á. Piñeiro, and S. Khalid Molecular dynamics simulations of phosphatidylcholine membranes: a comparative force field study J. Chem. Theory Comput. 8 2012 4593 4609
45. D. Poger, and A.E. Mark On the validation of molecular dynamics simulations of saturated and cis-monounsaturated phosphatidylcholine lipid bilayers: a comparison with experiment J. Chem. Theory Comput. 6 2009 325 336
46. A.W. Schuttelkopf, and D.M.F. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D 60 2004 1355 1363
47. A.K. Malde, L. Zuo, M. Breeze, M. Stroet, D. Poger, P.C. Nair, C. Oostenbrink, and A.E. Mark An automated force field topology builder (ATB) and repository: version 1.0 J. Chem. Theory Comput. 7 2011 4026 4037
48. B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 4 2008 435 447
49. D. van der Spoel, P.J. van Maaren, and C. Caleman GROMACS molecule & liquid database Bioinformatics 28 2012 752 753
50. B. Hess, H. Bekker, H.J.C. Berendsen, and J. Fraaije LINCS: a linear constraint solver for molecular simulations J. Comput. Chem. 18 1997 1463 1472
51. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J. Mol. Graph. 14 1996 33 38
52. C. Vitorino, J.J. Sousa, A.A.C.C. Canelas, Manuscript in preparation.
53. M. Piecha, M. Sarakha, P. Trebše, and D. Kočar Stability studies of cholesterol lowering statin drugs in aqueous samples using HPLC and LC-MS Environ. Chem. Lett. 8 2010 185 191
54. M. Jemal, Z. Ouyang, and M.L. Powell Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma J. Pharm. Biomed. Anal. 23 2000 323 340
55. W. Strober Trypan Blue Exclusion Test of Cell Viability, in: Current Protocols in Immunology 2001 John Wiley & Sons, Inc.
56. A. Cadete, L. Figueiredo, R. Lopes, C.C.R. Calado, A.J. Almeida, and L.M.D. Gonçalves Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles Eur. J. Pharm. Sci. 45 2012 451 458
57. R. Lopes, C.V. Eleutério, L.M.D. Gonçalves, M.E.M. Cruz, and A.J. Almeida Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis Eur. J. Pharm. Sci. 45 2012 442 450
58. R.K. Subedi, K.W. Kang, and H.-K. Choi Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin Eur. J. Pharm. Sci. 37 2009 508 513
59. A.C. Williams, and B.W. Barry Penetration enhancers Adv. Drug Deliv. Rev. 56 2004 603 618
60. H. Trommer, and R.H.H. Neubert Overcoming the stratum corneum: the modulation of skin penetration Skin Pharmacol. Physiol. 19 2006 106 121
61. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
62. K. Mäder, and W. Mehnert 1 - solid lipid nanoparticles - concepts, procedures, and physicochemical aspects C. Nastruzzi, Lipospheres in Drug Targets and Delivery: Approaches, Methods, and Applications 2004 CRC Press 1 22
63. T. Helgason, T.S. Awad, K. Kristbergsson, D.J. McClements, and J. Weiss Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN) J. Colloid Interface Sci. 334 2009 75 81
64. M.A. Iqbal, S. Md, J.K. Sahni, S. Baboota, S. Dang, and J. Ali Nanostructured lipid carriers system: recent advances in drug delivery J. Drug Target. 20 2012 813 830
65. R.B. Walker, and E.W. Smith The role of percutaneous penetration enhancers Adv. Drug Deliv. Rev. 18 1996 295 301
66. S.T.K. Narishetty, and R. Panchagnula Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation Biopharm. Drug Dispos. 25 2004 9 20
67. J.R. Kunta, V.R. Goskonda, H.O. Brotherton, M.A. Khan, and I.K. Reddy Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin J. Pharm. Sci. 86 1997 1369 1373
68. T.T. Kararli, C.F. Kirchhoff, and S.C. Penzotti Jr. Enhancement of transdermal transport of azidothymidine (AZT) with novel terpene and terpene-like enhancers: in vivo-in vitro correlations J. Control. Release 34 1995 43 51
69. A. Nokhodchi, K. Sharabiani, M.R. Rashidi, and T. Ghafourian The effect of terpene concentrations on the skin penetration of diclofenac sodium Int. J. Pharm. 335 2007 97 105
70. J.L.V. dos Anjos, and A. Alonso Terpenes increase the partitioning and molecular dynamics of an amphipathic spin label in stratum corneum membranes Int. J. Pharm. 350 2008 103 112
71. P.J. Perry, T. Sanger, and C. Beasley Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients J. Clin. Psychopharmacol. 17 1997 472 477
72. M. Tubic-Grozdanis, J. Hilfinger, G. Amidon, J. Kim, P. Kijek, P. Staubach, and P. Langguth Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms Pharm. Res. 25 2008 1591 1600
73. J.T. Callaghan, R.F. Bergstrom, L.R. Ptak, and C.M. Beasley Olanzapine: pharmacokinetic and pharmacodynamic profile Clin. Pharmacokinet. 37 1999 177 193
74. K. Bhaskar, C.K. Mohan, M. Lingam, S.J. Mohan, V. Venkateswarlu, Y.M. Rao, J. Anbu, and V. Ravichandran Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics Drug Dev. Ind. Pharm. 35 2009 98 113
75. R. Prasad, V. Koul, S. Anand, and R.K. Khar Effect of DC/mDC iontophoresis and terpenes on transdermal permeation of methotrexate: in vitro study Int. J. Pharm. 333 2007 70 78
76. K. Zhao, and J. Singh In vitro percutaneous absorption enhancement of propranolol hydrochloride through porcine epidermis by terpenes/ethanol J. Control. Release 62 1999 359 366
77. Test no. 439: In vitro skin irritation: reconstructed human epidermis test method OECD Guidelines for the Testing of Chemicals 1 2010 1 18
78. S. Küchler, M.R. Radowski, T. Blaschke, M. Dathe, J. Plendl, R. Haag, M. Schäfer-Korting, and K.D. Kramer Nanoparticles for skin penetration enhancement - A comparison of a dendritic core-multishell- nanotransporter and solid lipid nanoparticles Eur. J. Pharm. Biopharm. 71 2009 243 250